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Abstract
Background:  Myasthenic crisis is the most serious life-threatening event in generalized
myasthenia gravis (MG) patients. The objective of this study was to assess the long-term impact of
thymectomy on rate and severity of these attacks in Iranian patients.
Methods: We reviewed the clinical records from 272 myasthenic patients diagnosed and treated
in our neurology clinic during 1985 to 2002. Fifty-three patients were excluded because of
unconfirmed diagnosis, ocular form of MG, contraindication to surgery, concomitant diseases and
loss to follow-up. The Osserman classification was used to assess the initial severity of the disease.
Frequency and severity of the attacks were compared between two groups with appropriate
statistical tests according to the nature of variables. Multivariate logistic regression analysis was
used to assess the predictors of myasthenic crisis in the group of patients without thymoma.
Results: 110 patients were in thymectomy group and the other 109 patients were on medical
therapy. These two groups had no significant differences with respect to age at onset, gender,
Osserman score in baseline and follow up period. 62 patients (28.3% of all 219 patients) had
reported 89 attacks of myasthenic crisis. 20 patients of 62 (32%) were in thymectomy group and
42 (68%) were in the other group. There was significant difference between the two groups in
number of patients with crisis (P = 0.001; odds ratio = 2.8 with 95% CI of 1.5 to 5.2). In addition,
these attacks were more severe in group of non-thymectomized patients as the duration of ICU
admission was longer and they needed more ventilatory support during their attacks. Regression
model showed thymectomy and lower age at onset as two predictors of decrement in myasthenic
crisis rate in non-thymomatous MG patients.
Conclusions: It is suggested that frequency and severity of myasthenic attacks as important
endpoints in evaluation of MG patients. Thymectomy seems to have a preventive role on rate and
severity of these attacks.
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Background
Myasthenia Gravis (MG) is the mostly known autoim-
mune disease in human, mediated by autoantibodies
against the nicotinic receptor of acetylcholine in neu-
romuscular junctions [1]. Two cardinal features of this
disease are muscle weakness and fatigability. Although
periorbital area contains the only affected muscles in
some patients, generalized weakness develops in approxi-
mately 85% of patients, affecting bulbar and limb muscles
as well as the neck extensors and the diaphragm.
Myasthenic crisis refers to a rapid deterioration in neu-
romuscular function with respiratory compromise due to
ventilatory muscle insufficiency or weakness of upper air-
way musculature or both [1]. These attacks might be trig-
gered by multiple factors, including infections, physical or
emotional stresses, aspiration, electrolyte disturbances,
changes in medications and inadvertent administration of
non-depolarizing muscle relaxants or other drugs. In this
state, respiratory function should be monitored closely for
evidence of respiratory failure and ventilatory support
should be initiated in the setting of emerging respiratory
failure [2,3].
In general, four methods of treatment are currently in use
[4]: anticholinesterase agents, immunosuppressives, sur-
gical thymectomy, and short-term immunotherapies,
including plasma exchange and intravenous immune
globulin (IVIG). Since the first operation for MG in 1911
[5], thymectomy has become an increasingly accepted
procedure for treatment of MG, as it can help to achieve
complete clinical remission rate between 18% and 50%
[6-9] and clinical improvement in majority of patients
[10]. The rationale for thymectomy is that about 75% of
MG patients have thymic abnormalities; of these, 85%
have hyperplasia and 15% have thymoma [11].
Although there is no convincing evidence regarding the
use of thymectomy in non-thymomatous MG patients
[12,13], most authorities recommend this procedure in
all patients of ages between puberty and 60's [14,15].
However, this is not a general idea.
Thymectomy effects on occurrence and intensity of respi-
ratory crisis have not been studied yet. Concerning value
of this life-threatening event in MG patients, we studied
the role of thymectomy on long-term frequency and sever-
ity of these attacks.
Methods
We reviewed the clinical records from 272 myasthenic
patients diagnosed and treated in the neurology clinic of
Shariati Hospital, Tehran, during 1985 to 2002. All
included patients had positive history and physical exam-
ination, confirmed with positive Tensilon test and electro-
myography (with repetitive nerve stimulation test).
Searching for thymomas, all patients had a chest com-
puted tomography (CT) scan.
The following patients were excluded from the study: 3
patients with doubtful test results and unconfirmed diag-
nosis; 25 patients with ocular form of MG (as these
patients have no presentation of crisis); 2 patients with
thymoma (and two episodes of crisis in the previous
year), but contraindicated for surgery because of coronary
artery disease; 6 patients with thyroid function abnormal-
ities (because of their known effects on induction and
reduction of myasthenic crises); 2 patients with concomi-
tant rheumatoid arthritis (and consumption of high doses
of corticosteroids and immunosuppressives); and 15
patients lost from follow-up with incomplete data. 219
MG patients enrolled in the study.
Myasthenic crisis was defined as an attack that compels
physicians to hospitalize the patient and carefully super-
vise patient's respiratory capacity [3]. In most of these
conditions, ventilatory support was needed. However,
sometimes patient could be managed without intubation
as a result of spontaneous improvement or use of plas-
mapheresis or IVIG.
All included patients were eligible for surgery. Patients
with CT confirmed thymoma underwent elective thymec-
tomy as soon as possible. In the first visit after diagnosis
confirmation in non-thymomatous patients, the advan-
tages and drawbacks of operation (including risks of
anesthesia in MG patients) had been explained to them
and deciding between the two choices of thymectomy or
conservative therapy had been left to the agreement
between physicians and patients. No particular protocol
had been established for these patients and physicians
had only a consultant role for patients with no force on
them.
For clinical assessment of the initial severity of the disease,
the classification of Osserman [16] had been applied to all
patients in the first visit and inserted into patient's clinical
profile. In following visits, patients' condition has been
referred to this initial assessment. Data were collected on
demographic factors, disease course at the first year of
onset (or the year before surgery in thymectomized
patients), time of surgery, pathology report, number of
myasthenic crises (post-op in thymectomized patients),
precipitating factors for attacks, ICU admission and the
need for respiratory support, plasmapheresis or IVIG in
each attack. 12 patients in thymectomy group had history
of myasthenic crisis before surgery that were not
considered.BMC Neurology 2004, 4:12 http://www.biomedcentral.com/1471-2377/4/12
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The participants' baseline characteristics and follow-up
data were analyzed by Student's t test and analysis of var-
iances (ANOVA) as parametric tests, Mann-Whitney U test
as non-parametric test, and Pearson's chi-square test for
qualitative differences (SPSS software, version 10.0). P
values less than 0.05 were taken to indicate statistical sig-
nificance. Continuous variables are shown as the mean ±
standard deviation (SD) and non-parametric variables
with their median and range. Odds ratios and relative
risks with 95% confidence intervals (95% CI) were calcu-
lated to assess the proportional risk of crisis between two
groups.
In the subgroup of patients without thymoma, multivari-
ate logistic regression analysis was used to assess the rela-
tionship between frequency of myasthenic crisis and
several risk factors such as sex, start age of the disease,
Osserman score and thymectomy. According to its percen-
tile, start age was divided into three categories as bottom
one-third (under percentile 33), middle one-third
(between percentiles 34 and 66), and top one-third (over
percentile 67).
Results
110 patients underwent thymectomy (76 by trans-sternal
and 34 by trans-cervical approaches) and 109 patients
were on conservative therapy. Baseline characteristics and
follow-up periods are shown in Table 1. Time interval
between onset of myasthenic symptoms and thymectomy
ranged from 1 to 192 months with median of 12. Mean
age at thymectomy was 30.3 ± 12.8 years. During follow-
up period, each patient had about 13 visits on average.
Totally, 62 patients in both groups experienced 89 attacks
of respiratory failure during their follow-up, which
accounts for 28.3% of the study population. As it is shown
in Table 2, 18.2% of thymectomized patients (20 of 110)
and 38.5% of non-thymectomized patients (42 of 109)
had history of these attacks. The difference between two
groups was significant in this regard. Additionally, Odds
ratio for being affected twice or more among patients on
conservative therapy was 4.2 (with 95% CI of 1.1 to 16.7).
Three patients in thymectomy group had history of crisis
during post-op period in the hospital. Main triggering
factors for myasthenic crises were lack of compliance to
the drugs, pneumonia, and unknown causes Table 3.
To assess the severity of each attack, we considered dura-
tion of ICU admission (days), need to respiratory support
and need to plasmapheresis or IVIG during crisis as indi-
cating variables. As it is shown in Table 4 myasthenic cri-
ses were almost more severe in patients under
conservative therapy. Two patients (both on conservative
therapy) had passed away during respiratory failure (mor-
tality rate = 2/89 = 2.2%) and these conditions were so
protracted in some of patients that they were confined to
ICU beds for more than one month.
Pathology reports in thymectomized patients revealed 16
cases of thymoma. Fifty percent of these patients (8 of 16)
had experienced crisis, which accounts for 40% (8 of 20)
of thymectomized patients with history of crisis. Mann-
Whitney  U  test revealed significant difference in this
regard (P < 0.001). Severity indexes did not differ signifi-
cantly between thymomatous and non-thymomatous
patients Table 5.
Totally, there were 203 patients without thymoma.
Regression analysis in this subgroup of patients revealed
that group of non-thymectomized patients as well as two
third of patients with higher ages at the beginning of the
disease were more prone to respiratory attacks Table 6.
Table 1: Characteristics of thymectomized patients just before thymectomy and non-thymectomized patients at the first year of the 
diagnosis
Thymectomized patients 
(n = 110)
Non-thymectomized patients 
(n = 109)
P value
Age at diagnosis (years) 29.2 ± 13.7 33.0 ± 15.9 0.059
Gender (male/female) 41/69 53/56 0.089
Osserman Score* = I 0 0
Osserman Score = IIa 46 48
Osserman Score = IIb 37 50
Osserman Score = III 25 11
Osserman Score = IV 2 0
Follow up period (years) 6.4 ± 4.3 7.9 ± 5.6 0.134
* Mann-Whitney U test showed no significant difference between two groups (Z = |1.421| & P = 0.155)BMC Neurology 2004, 4:12 http://www.biomedcentral.com/1471-2377/4/12
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Table 2: relation between myasthenic crisis frequency and thymectomy
Thymectomized patients 
(n = 110)
Non-thymectomized patients 
(n = 109)
P value
Patients with myasthenic crisis (n = 62) 20 42* 0.001
Episodes of myasthenic crisis (n = 89) 25 64† 0.016
* This group had more probability of having crisis with an odds ratio of 2.8 (with 95% confidence interval of 1.5 to 5.2)
†Myasthenic crises were more prevalent in this group with a relative risk of 2.6 (with 95% confidence interval of 1.8 to 3.8)
Table 3: Characteristics of patients with myasthenic crisis in thymectomized and non-thymectomized patients*
Thymectomized patients (n = 20) Non-thymectomized patients (n = 42)
Age at diagnosis (years) 31.4 ± 10.6 30.5 ± 12.7
Age at first crisis (years) 33.5 ± 11.2 34.1 ± 11.3
Gender (male/female) 6/14 20/22
Triggering factors
Pneumonia 3 (15%) 13 (30%)
Other infections 2 (10%) 4 (10%)
Aspiration 2 (10%) 3 (7%)
Stresses† 1 (5%) 2 (5%)
Drug intolerance 8 (40%) 10 (24%)
No obvious cause 4 (20%) 10 (24%)
* There were no statistical differences between two groups
† Refers to physical and emotional stresses as well as menstruation
Table 4: Severity parameters for each attack in patients with myasthenic crisis
Thymectomized patients 
(n = 25)
Non-thymectomized patients 
(n = 64)
P value*
Median Days in ICU (Range) 7(2–38) 12(2–55) 0.044
Need to Ventilatory support 19 (76%) 59 (92%) 0.037
Need to Plasmapheresis or IVIG 7 (28%) 23 (36%) 0.476
* P values from chi-square test for assessment of difference between two groups
Table 5: Characteristics of thymectomized patients with respect to pathology of thymus
Thymus 
Pathology
N (% of 110) Age at diagnosis* 
(years)
Sex (m/f) Patients with 
Myasthenic 
crisis (%)
Number of 
Myasthenic 
crisis
Days in ICU 
(Median & Range)
Ventilatory 
support
Normal 51 (46.4%) 29.7 ± 13.9 18/33 3 (5.9%) 3 3 & 2–4 3
Hyperplasia 43 (39.1%) 27.4 ± 15.2 14/29 9 (20.9%) 10 7 & 2–30 7
Thymoma 16 (14.5%) 37.3 ± 8.9 9/7 8 (50.0%) 12 9 & 3–38 9
* Analysis of variances indicated that age at diagnosis in thymomatous patients was significantly higher than others (P = 0.007). There was no statistically 
significant difference regarding other variables.BMC Neurology 2004, 4:12 http://www.biomedcentral.com/1471-2377/4/12
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Discussion
Persuasive evidence for thymectomy in non-thymoma-
tous generalized myasthenic patients is not on hand. In an
attempt to establish standards in this regard, American
Academy of Neurology advised thymectomy as only an
option to increase the probability of remission or improve-
ment in these patients [13]. In this review, thymectomy
was associated with a median relative rate of medication
free remission of 2.1 and a relative rate of improvement of
1.7. However, these improvements were significant in
only a small number of the studies reviewed and the
majority did not show a significant benefit with
thymectomy. In addition, none of the studies was rand-
omized or used blinded outcome assessments, and in
most thymectomy was performed in younger patients.
Surprisingly, none of these studies has considered
myasthenic crisis frequency as their study endpoint. For
instance, in the study of Cohen et al. in 1981, 15 of 28
thymectomized patients experienced 21 crises during fol-
low-up period [17]. In another study, 13 of 27 patients
with crisis had previous thymectomy, six with thymoma
[18]. This study was the first one that sought thymectomy
impact on occurrence of crisis.
In our experience, persistence on thymectomy for all
myasthenic patients would not be so wisely. Response to
thymectomy is highly variable among these patients.
Method of gaining agreement between physicians and
patients would bring some benefits. As it is shown in
Table 3, rate of intolerance to drugs was lower among the
patients who preferred medical therapy. However, it is
notable that there is a general tendency among both phy-
sicians and patients towards operation in younger ages
and in patients with more severe course. In this study,
thymectomized patients were about 4 years younger on
average and had higher Osserman scores at the beginning
(Table 1); but the difference was not statistically signifi-
cant because of large study population and dispersion of
baseline characteristics.
When myasthenic crisis occurrence is considered as the
main endpoint of treatment in myasthenic patients,
thymectomy has a great impact. Patients on conservative
therapy had risk of about 3-fold of thymectomized
patients to encounter respiratory attacks. However, the
overall frequency of myasthenic crisis among our study
population could be considered more than similar reports
[2,4], perhaps reflecting some unidentified racial differ-
ences or lower compliance of Iranian patients to continu-
ous medications.
Some previous studies have shown the benefit of thymec-
tomy in the control of symptoms of MG. It has been
revealed that delay in surgery could worsen the prognosis
of MG [19] and the chance of benefiting from thymec-
tomy increases when the history of MG is short and the
stage of the disease is early [20]. Concerning differences of
thymectomy effects in thymomatous and non-thymoma-
tous patients, several studies have been conducted previ-
ously, showing some discrepancies in the results [21-23].
According to this study, thymomatous patients are more
prone to respiratory attacks compared with all other MG
patients. However, their attacks are not drastically differ-
ent in severity of complications.
During myasthenic crisis, Weakness of the respiratory
muscles may be out of proportion to that of other skeletal
muscles. In rare cases, ventilatory failure is the only
clinically apparent manifestation of the disease [24,25].
In addition, sometimes prediction of incoming attack is
very difficult. In the present study, a 27-year-old woman
experienced an attack after 7 months of complete remis-
sion on no drug.
Generally, infection is the most common trigger for
myasthenic crisis [1]. Higher rate of infection in non-
thymectomized patients in this study could be logically
due to higher amounts of immunosuppressives in the
medication regimen of these patients that we could not
evaluate in this study. However, concerning frequency of
myasthenic crises, this reduction of immunosuppressives
in the regimen of thymectomized patients could be inter-
Table 6: logistic regression model for predictors of myasthenic crisis among patients without thymoma (n = 203).
Predictors Odds Ratio Lower 95% CI Upper 95% CI P value
Start age (years) 1.016 0.996 1.038 0.085
Sex (male) 0.926 0.482 1.778 0.612
Thymectomy (performed) 0.234 0.113 0.484 <0.001
Osserman classification 
(score III)
1.269 0.410 3.928 0.529
Start age category (one 
third of younger patients)
0.272 0.097 0.759 0.021BMC Neurology 2004, 4:12 http://www.biomedcentral.com/1471-2377/4/12
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preted as an important benefit of thymectomy in MG
patients.
The main limitation of this study was its retrospective
design and the lack of randomization. Apparently, within
a period of 17 years, many changes have occurred to diag-
nostic and therapeutic facilities as well as knowledge and
attitude of physicians. These changes could have signifi-
cant consequences on the outcome of myasthenic
patients. Although various operative approaches seem not
to differ drastically [26], various types of immunosuppres-
sives and dosage of them have important role in the prog-
nosis of patients, which we did not assess them in this
study. We also could not gather information about acetyl-
choline receptor antibodies, which play an important role
in the pathophysiology of MG. Further studies concerning
the role of these antibodies in the occurrence and severity
of myasthenic crises are required.
Conclusions
In conclusion, we suggest evaluation of various aspects of
myasthenic crisis as an important endpoint in long-term
assessment of generalized MG patients. Moreover, we
showed that thymectomy has a preventive role on rate and
severity of myasthenic attacks in age and disease severity
matched groups of patients. However, this effect needs
further evaluation in upcoming prospective studies.
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